553 Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade (ICB) in patients with oropharyngeal carcinoma (OPC)

Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Qingnan Liang, Jinzhuang Duo, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, Keiko Akagi, Weihong Xiao, Shaoheng Liang, Satvik Elayavalli, Baohua Sun, Edwin R. Parra, Renata Ferrarotto, Adam S. Garden, Clifton D. Fuller, Jay P. Reddy, Neil D. Gross, Miriam N. Lango, Cheuk Hong Leung, Suyu Liu, Diane Liu, Meng Li, J. Jack Lee, Michael A. Curran, Jack Phan, Ken Chen, Maura L. GillisonRegular 2024 · DOI

Abstract

Pathological response to neoadjuvant immune checkpoint blockade (ICB) is a key biomarker for long-term disease control. This study investigated the tumor microenvironment (TME) features associated with major histological response (MHR) in HPV-positive oropharyngeal carcinoma (OPC) patients treated with induction ipilimumab and nivolumab. Using single-cell profiling of matched biopsies, we identified that MHR is characterized by a higher baseline proportion of $Fc\gamma RIIIa+$ (CD16+) NK cells and a significant on-treatment depletion of effector regulatory T (eTreg) cells. This depletion correlates with the expansion of $IFNG+$ effector CD8+ T cells, suggesting a critical role for the NK-eTreg axis in driving clinical response.

Introduction

Neoadjuvant ICB has emerged as a promising strategy to improve outcomes in solid tumors. In HPV-positive OPC, understanding why some patients achieve an MHR—defined as <10% residual tumor viability—while others do not is crucial for personalizing therapy. This study explores the cellular dynamics within the TME that underpin successful dual ICB treatment using high-resolution single-cell sequencing.

Methods

A phase 2 trial (NCT03799445) enrolled 35 patients with newly diagnosed HPV-positive OPC. Patients received a 6-week induction cycle of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). Biopsies were collected at baseline and on-treatment. Researchers performed single-cell RNA sequencing (scRNA-seq) and T-cell receptor sequencing (scTCR-seq) on over 150,000 T cells to track clonotype transitions and gene expression changes. Clinical response was assessed by a masked pathologist.

Results

The induction therapy yielded a 46% MHR rate, with high 6-month complete metabolic response (94%) and 2-year progression-free survival (84%).

The NK-eTreg Axis

A pivotal finding was the association between MHR and the dynamics of NK and eTreg cells. Responders exhibited significantly higher baseline levels of intratumoral $CD16+$ ($Fc\gamma RIIIa+$) NK cells compared to non-responders.

Baseline CD16+ NK cell proportions are significantly higher in patients who achieve a major histological response (MHR).

Furthermore, MHR patients showed a marked reduction in eTreg cells during treatment, a shift not observed in non-responders. These eTregs highly express CTLA-4, making them susceptible to depletion by $Fc\gamma RIIIa+$ NK cells via antibody-dependent cellular cytotoxicity (ADCC) likely induced by the anti-CTLA-4 agent ipilimumab.

On-treatment depletion of effector regulatory T (eTreg) cells is specifically observed in patients achieving MHR, whereas levels remain stable in non-responders.

T-cell Plasticity and Predictive Modeling

eTreg depletion directly correlated with an increase in $IFNG+$ effector CD8+ T cells. TCR tracking revealed a remarkable degree of plasticity: in MHRs, CD8+ T-cell clonotypes transitioned from tissue-resident memory (TRM) states to effector memory (TEM) and active killer phenotypes. In contrast, non-responders saw these same clonotypes move toward exhaustion and proliferation.

To translate these findings into a clinical tool, a LASSO regression model was developed using baseline TME features. By incorporating NK cell proportions, CD8+ cytotoxicity scores, and immune checkpoint scores, the model predicted the percentage reduction in tumor viability with high accuracy ($R^2 = 0.89$).

Conclusion

Successful response to dual ICB in HPV-positive OPC is driven by a pre-existing antitumor immune environment and the successful removal of immunosuppressive "brakes." The depletion of eTregs, likely mediated by NK cells, is a critical step that allows for the expansion and activation of killer T cells. These findings highlight potential biomarkers for predicting response and suggest that targeting the NK-eTreg axis could enhance the efficacy of immunotherapy in head and neck cancers.

Summary updated

Abstract

<h3>Background</h3> Pathological response to neoadjuvant ICB is established as a biomarker of long-term disease control in several solid tumors.<sup>1</sup> To determine tumor microenvironment (TME) features associated with pathological response, we performed single-cell profiling on matched baseline and on-treatment tumor biopsies from patients with newly diagnosed HPV-positive OPC enrolled in a phase 2 trial of a 6-week cycle of induction ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) prior to radiotherapy.<sup>2 3</sup> <h3>Methods</h3> Five 2-millimeter cores from tumor biopsies from 35 patients were formalin-fixed and paraffin-embedded (FFPE) or immediately processed for scRNA-seq and scTCR-seq on the 10X Genomics and Illumina platforms. A pathologist masked to clinical response evaluated FFPE for percent tumor viability, and a major histological response (MHR) was defined as &lt;10% residual tumor viability on treatment. After stringent clustering and annotation of single-cell data, 76,319 CD8+ and 78,622 CD4+ T cells with paired TCR-seq data were identified for comprehensive transcriptomic, TCR repertoire and clonotype analysis and associations with MHR. <h3>Results</h3> Co-primary endpoints achieved included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% MHR rate. Single-cell profiling revealed MHRs had higher baseline intratumoral NK cells expressing Fc Gamma Receptor IIIa (Fcg+) (figure 1). Decreases in effector regulatory T (eTreg) cells, which highly expressed CTLA4, occurred only in MHRs, suggesting ipilimumab-dependent depletion<sup>4</sup> by Fcg+ NK cells (figure 1). eTreg depletion correlated with increased Interferon Gamma (IFNG)+ effector<sup>5</sup> CD8+ T cells (figure 2). CD8+ T-cell clonotypes transitioned from tissue resident memory (TRM), a phenotype more enriched in MHRs at baseline, to effector memory (TEM) and IFNG+ effector cells in MHRs, whereas clonotypes transitioned to exhausted TRM and proliferating cells in nonMHRs (figure 3). Basal TME features including Fcg+ NK proportion, CD8+ cytotoxicity score and immune checkpoint score are associated with percent reduction in tumor viability (R<sup>2</sup> =0.89) in a predictive lasso regression model (figure 4). <h3>Conclusions</h3> We identified TME features associated with tumor cell death in HPV-positive OPC. Of them, eTreg depletion is critical for major response to induction dual PD-1 and CTLA-4 ICB and potentially induced by Fcg+ NK mediated ADCC. Additionally, a pre-existing antitumor immune response mediated by CD8+ T cells was associated with MHR to the dual ICB. Treatment led to Treg depletion and expansion of CD8+ T cell clonotypes with TRM and TEM phenotypes, revealing a remarkable degree of plasticity of distinct T cell clonotypes. <h3>Acknowledgements</h3> This study was funded by CPRIT. MLG is a CPRIT Scholar in Cancer Research. <h3>Trial Registration</h3> NCT03799445. <h3>References</h3> Stein JE, <i>et al</i>. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. <i>Ann Oncol</i> 2019;<b>30</b>:589–596. Jiang X, <i>et al</i>. Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade.<i> medRxiv</i> 2024.2001.2004.23300616 (2024). Vos JL, <i>et al</i>. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.<i> Nat Commun</i> 2021;<b>12</b>:7348. Romano E, <i>et al</i>. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.<i> Proc Natl Acad Sci U S A</i> 2015;<b>112</b>:6140–6145. Ivashkiv LB. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. <i>Nat Rev Immunol</i> 2018;<b>18</b>:545–558. <h3>Ethics Approval</h3> The study was approved by MD Anderson institution’s Ethics Board, approval numbers 2018-0381 and PA19-0470.
BibTeX
@inproceedings{jiang2024depletion,
  author = {Xianli Jiang and Nils-Petter Rudqvist and Bo Jiang and Shengbin Ye and Qingnan Liang and Jinzhuang Duo and Michelle D. Williams and Joe Dan Dunn and Jason M. Johnson and Keiko Akagi and Weihong Xiao and Shaoheng Liang and Satvik Elayavalli and Baohua Sun and Edwin R. Parra and Renata Ferrarotto and Adam S. Garden and Clifton D. Fuller and Jay P. Reddy and Neil D. Gross and Miriam N. Lango and Cheuk Hong Leung and Suyu Liu and Diane Liu and Meng Li and J. Jack Lee and Michael A. Curran and Jack Phan and Ken Chen and Maura L. Gillison},
  title = {{553 Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade (ICB) in patients with oropharyngeal carcinoma (OPC)}},
  booktitle = {Regular},
  year = {2024},
  doi = {10.1136/jitc-2024-sitc2024.0553},
}
Figure